All funds

Arctic Aurora LifeScience B NOK

Equity fund

1 year

Globe

USA

Largest region

Medium

Risk

Annual costs

Morningstar

 

Partial 

Sustainability

Development

Last 5 years
( ann.)

Details

  • Fondets målsetting er å øke verdien av andelseiernes investering gjennom å investere i aksjer globalt innenfor sektorer som farmasi, bioteknologi o.l.
    Read more

Investment horizon

  • Arctic Aurora LifeScience B NOK is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.

Characteristics

  • Minimum amount
  • Sharpe 3 years
  • NAV/Price

    08 Dec 2025

  • Margin rate
  • Start date
    30 Mar 2017
  • ISIN
    IE00BYQ7ZM91

Risk

  • Medium (4 of 7)

Morningstar rating

  • The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.

Sustainability

Annual cost

  • Ongoing costs

    Includes management fees of 1,25 %

  • Platform fee
  • Kickback fee
  • Annual running costs

Other costs

  • Performance-based fee
  • Transaction costs

  • Costs for any currency exchanges are not included.

Allocation

  • Stocks 99%
    Interest 1%

Portfolio

Shows the fund's largest investments.

  • Eli Lilly and Co
    7.0%
  • AstraZeneca PLC
    5.3%
  • Alltrna, Inc - Common Stock
    3.3%
  • argenx SE
    3.0%
  • Arcutis Biotherapeutics Inc Ordinary Shares
    2.8%
  • Novartis AG Registered Shares
    2.6%
  • Thermo Fisher Scientific Inc
    2.6%
  • BridgeBio Pharma Inc
    2.3%
  • Crinetics Pharmaceuticals Inc
    2.3%
  • Johnson & Johnson
    2.3%